Evotec (NASDAQ:EVO) Sees Large Volume Increase - Here's Why

Key Points

• Evotec experienced a midday trading volume surge of 51% to 205,273 shares, with the stock trading around $2.545 (previous close $2.62).
• Analyst views are mixed—three Buys, one Hold and one Sell—resulting in a MarketBeat consensus rating of Hold and a consensus target price of $7.00.
• Institutional activity picked up as firms like Wellington, Citadel, Millennium and Jane Street adjusted positions, with overall institutional ownership near 5.81%.

Evotec AG (NASDAQ:EVO - Get Free Report) shares saw strong trading volume on Tuesday . 205,273 shares traded hands during mid-day trading, an increase of 51% from the previous session's volume of 136,383 shares.The stock last traded at $2.5450 and had previously closed at $2.62.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Evotec from a "sell" rating to a "hold" rating in a report on Saturday, January 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Evotec in a report on Monday, December 29th. Finally, Berenberg Bank assumed coverage on Evotec in a report on Tuesday, February 3rd. They issued a "buy" rating for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Evotec has a consensus rating of "Hold" and a consensus target price of $7.00.

Evotec Price Performance

The business has a fifty day moving average price of $3.07 and a 200 day moving average price of $3.32. The company has a current ratio of 2.12, a quick ratio of 2.03 and a debt-to-equity ratio of 0.48.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Pitcairn Co. acquired a new position in shares of Evotec during the second quarter worth approximately $1,097,000. Millennium Management LLC acquired a new position in shares of Evotec during the fourth quarter worth approximately $317,000. Citadel Advisors LLC lifted its holdings in shares of Evotec by 186.1% during the third quarter. Citadel Advisors LLC now owns 96,045 shares of the company's stock worth $349,000 after buying an additional 62,471 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Evotec during the fourth quarter worth approximately $565,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company's stock worth $5,536,000 after buying an additional 367,545 shares during the last quarter. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.